Skip to main content

Table 4 Proportion of patients who tapered their dosage of inhaled corticosteroids in the montelukast add-on group

From: Effectiveness of montelukast administered as monotherapy or in combination with inhaled corticosteroid in pediatric patients with uncontrolled asthma: a prospective cohort study

 

Duration of treatment

 

Baseline

4 weeks

8 weeks

12 weeks

All patients

328

320

197

288

Use of ICS, n

    

   Yes

252

245

159

220

   No

76

75

38

68

Tapered ICS, n (%)

    

   Yes*

-

45 (18.4)

40 (25.2)

44 (20.0)

   No

-

194 (79.2)

117 (73.6)

175 (79.5)

   Missing

-

6 (2.4)

2 (1.3)

1 (0.5)

Preschool aged patients

146

140

93

128

Use of ICS, n

    

   Yes

112

106

72

96

   No

34

34

21

32

Tapered ICS, n (%)

    

   Yes

-

21 (19.8)

20 (27.8)

19 (19.8)

   No

-

82 (77.4)

50 (69.4)

76 (79.2)

   Missing

-

3 (2.8)

2 (2.8)

1 (1.0)

School aged patients

182

180

104

160

Use of ICS, n

    

   Yes

140

139

87

124

   No

42

41

17

36

Tapered ICS, n (%)

    

   Yes

-

24 (17.3)

20 (23.0)

25 (20.2)

   No

-

112 (80.6)

67 (77.0)

99 (79.8)

   Missing

-

3 (2.2)

0 (0.0)

0 (0.0)

  1. *There were 45 patients who newly tapered their ICS at 4 weeks, 17 at 8 weeks and 9 at 12 weeks.
  2. There were 21 preschool aged patients who newly tapered their ICS at 4 weeks, 8 at 8 weeks and 3 at 12 weeks.
  3. There were 24 school aged patients who newly tapered their ICS at 4 weeks, 9 at 8 weeks and 6 at 12 weeks.